Alterations of serum and placental endoglin in pre-eclampsia

Journal of International Medical Research

Volumn 38, Issue 1, 2010, Pages 43-51

  Fang, M ^a   He, Yao ^a   Li, H ^a   Wu, M ^a   Shi, X ^a   Du, H ^a  

^a Shaoxing Women and Children Hospital   (China)

Author keywords

Endoglin; Placenta; Pre eclampsia; Predictors; Pregnancy; Second trimester

Indexed keywords

CREATININE; ENDOGLIN; PLACENTA PROTEIN;

ADULT; ARTICLE; BIRTH; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE SEVERITY; ENDOGLIN BLOOD LEVEL; ENDOGLIN PLACENTA LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIGASTRIC PAIN; FEMALE; GESTATIONAL AGE; HEADACHE; HOMOGENATE; HUMAN; HUMAN TISSUE; INTRAUTERINE GROWTH RETARDATION; LUNG EDEMA; OLIGOHYDRAMNIOS; OLIGURIA; PATHOGENESIS; PLACENTA; PREECLAMPSIA; PREGNANT WOMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; VISUAL DISORDER;

EID: 77749301755     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001003800105     Document Type: Article

References (25)

1. Sibai B, Dekker G, Kupferminc M: Pre-eclampsia. Lancet 2005; 365: 785-799.
2. Tsatsaris V, Fournier T, Winer N: Pathophysiology of preeclampsia. J Gynecol Obstet Biol Reprod (Paris) 2008; 37: 16-23 [in French].
3. Gilbert JS, Ryan MJ, LaMarca BB, et al: Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol 2008; 294: H541-H550.
4. Huppertz B: Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 2008; 51: 970-975.
5. Maynard SE, Min JY, Merchan J, et al: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2002; 111: 649-658.
6. Taylor RN, Grimwood J, Taylor RS, et al: Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003; 188: 177-182.
7. Levine RJ, Maynard SE, Qian C, et al: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683.
8. Chaiworapongsa T, Romero R, Kim YM, et al: Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 7: 3-18.
9. Venkatesha S, Toporsian M, Lam C, et al: Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12: 642-649.
10. Dallas NA, Samuel S, Xia L, et al: Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 2008; 14: 1931-1937.
11. Toporsian M, Gros R, Kabir MG, et al: A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res 2005; 96: 684-692.
12. Levine RJ, Lam C, Qian C, et al: Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992-1005.
13. American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice: ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Int J Gynecol Obstet 2002; 77: 67-75.
14. Bradford, MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
15. Staff AC, Braekke K, Johnsen GM, et al: Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia. Am J Obstet Gynecol 2007; 197: 176.e1-176.e6.
16. Salahuddin S, Lee Y, Vadnais M, et al: Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol 2007; 197: 28.e1-28.e6.
17. Jeyabalan A, McGonigal S, Gilmour C, et al: Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia. Placenta 2008; 29: 555-563.
18. De Vivo A, Baviera G, Giordano D, et al: Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 2008; 87: 837-842.
19. Farina A, Sekizawa A, De Sanctis P, et al: Gene expression in chorionic villous samples at 11 weeks' gestation from women destined to develop preeclampsia. Prenat Diagn 2008; 28: 956-961.
20. Gilbert JS, Gilbert SA, Arany M, et al: Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. Hypertension 2009; 53: 399-403.
21. Munaut C, Lorquet S, Pequeux C, et al: Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast. Hum Reprod 2008; 23: 1407-1415.
22. Yinon Y, Nevo O, Xu J, et al: Severe intrauterine growth restriction pregnancies have increased placental endoglin levels: hypoxic regulation via transforming growth factor-β3. Am J Pathol 2008; 172: 77-85.
23. Gu Y, Lewis DF, Wang Y: Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2008; 93: 260-266.
24. Baumann MU, Bersinger NA, Mohaupt MG, et al: First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 2008; 199: 266.e1-266.e6.
25. Savvidou MD, Noori M, Anderson JM, et al: Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation. Ultrasound Obstet Gynecol 2008; 32: 871-876.